-- Company presentation scheduled for March 7th, 2017 at 9:20 a.m. ET --
SOUTH SAN FRANCISCO, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage
biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today
announced that the Company will be presenting at the Cowen and Company 37th Annual Health Care Conference in Boston.
Achaogen management will present at 9:20 a.m. Eastern Time on Tuesday, March 7th, 2017.
A live audio webcast of the presentation will be available in the "Investors" section of Achaogen’s website,
www.achaogen.com. A replay of the presentation will be archived for 30 days following the
conference for those unable to listen live.
About Achaogen
Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and
commercialization of innovative antibacterial treatments for MDR gram-negative infections. Achaogen is developing plazomicin,
Achaogen’s lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including
carbapenem-resistant Enterobacteriaceae. Achaogen’s plazomicin program is funded in part with a contract from the Biomedical
Advanced Research and Development Authority. Plazomicin is the first clinical candidate from Achaogen’s gram-negative antibiotic
discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative
infections. All product candidates are investigational only and have not been approved for commercialization. For more information,
please visit www.achaogen.com.
Source: Achaogen, Inc.
Investor Contact: Hans Vitzthum 212.915.2568 hans@lifesciadvisors.com Media Contact: Denise Powell 510.703.9491 denise@redhousecomms.com
